Showing 3611-3620 of 7549 results for "".
- FDA Approves Pfizer's Cibinqo for Moderate-to-Severe AD in Adultshttps://practicaldermatology.com/news/fda-approves-pfizers-cibinqo-for-moderate-to-severe-ad-in-adults/2461037/Pfizer's Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, is now FDA approved for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including bi
- FDA Approves Rinvoq for Adults and Children 12 Years and Older with Refractory, Moderate to Severe ADhttps://practicaldermatology.com/news/us-fda-approves-rinvoq-for-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-ad/2461036/The FDA has given its nod to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including bio
- Dermatologists Seeing High Rates of Hair Loss after COVID-19https://practicaldermatology.com/news/dermatologists-seeing-high-rates-of-hair-loss-after-covid-19/2461034/When Paula Diaz contracted COVID, she expected to lose her sense of smell and taste but not her hair. “I spent six days in the hospital being treated for the virus and several weeks after I came home, my hair started falling out in clumps,” says Paula, who added that s
- Vial Launches Dermatology CROhttps://practicaldermatology.com/news/vial-launches-dermatology-cro/2461031/Vial has launched the Vial Dermatology CRO, dubbing it “The CRO Built for Sponsors.” The San Francisco-based company will rely on a clinic network of more than 35 dermatology clinics across the country to re
- Cybersecurity Firm Offers Tips to Protect Dermatology Practice Datahttps://practicaldermatology.com/news/cybersecurity-firm-offers-tips-to-protect-dermatology-practice-data/2461029/Ransomware attacks continue to target the healthcare sector. Black Talon Security, a leading NY-based national cybersecurity firm, offers 10 tips that all dermatology practices should follow to keep data secure and protect patient r
- Avita Medical's Spray-On Skin Cells Demonstrate Proof of Concept in Aging Skin and EBhttps://practicaldermatology.com/news/avita-medicals-spray-on-skin-cells-demonstrate-proof-of-concept-in-rejuvenation-and-eb/2461028/Preclinical data successfully established proof of concept for Avita Medical’s Spray-On Skin Cells in skin rejuvenation and epidermolysis bullosa (EB), the company reports. AVITA Medical’s first US product, the RECELL System, was approved by FDA in September 2018.
- Drug Combination Boosts Progression-free Survival in Advanced Melanomahttps://practicaldermatology.com/news/drug-combination-boosts-progression-free-survival-in-advanced-melanoma/2461027/Combining relatlimab and nivolumab (Opdivo) may double progression-free survival in patients with advanced melanoma, according to a new study in the New England Journal of Medicine. Relatlimab, which blocks
- Galderma Completes Alastin Acquisitionhttps://practicaldermatology.com/news/galderma-completes-alastin-acquisition/2461026/Having received antitrust clearance from US authorities, Galderma has completed the acquisition of Alastin Skincare®, Inc., a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispens
- Survey: Consumers Interested in Medical Cannabis Products for Inflammatory Skin Disordershttps://practicaldermatology.com/news/survey-consumers-interested-in-medical-cannabis-products-for-inflammatory-skin-disorders/2461025/Patients with dermatologic conditions are open to trying medical cannabis products (MCPs) as potential treatments, according to a new study from George Washington University (GW) School of Medicine and Health Sciences (SMHS) and University of Maryland researchers. “MCPs, which are
- Dermatologist Tackles Misinformation Related to COVID-19 Vaccines and Injectable Fillers and Toxinxhttps://practicaldermatology.com/news/dermatologist-tackles-misinformation-related-to-covid-19-vaccines-and-injectable-fillers/2461022/With a recent article in the Wall Street Journal article suggesting that patients must choose between neurotoxin treatments or COVID-19 vaccines, dermatologists are scurrying to set the record straight. While there have been rare reports of non-life-threatening, transient reactions